Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$26.04 USD
+0.53 (2.08%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $26.16 +0.12 (0.46%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BEAM 26.04 +0.53(2.08%)
Will BEAM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Other News for BEAM
Hold Rating on Beam Therapeutics Amid Competitive Pressure and Absence of Clinical Data
Beam Therapeutics initiated with neutral view at JonesResearch, here's why
Beam Therapeutics price target raised to $69 from $66 at Stifel
Intellia Therapeutics price target lowered by $16 at Stifel, here's why
Krystal Biotech price target raised to $220 from $204 at Stifel